RxDoctor Payments DataLook up a doctor →

Laura Giusto, MD

Urology · Owings Mills, MDNPI 1205118296

Payments from drug & device makers

$628,054in general payments, 2019–2025

Across 1,032 payments — averaging $608.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$332K
  • Bluewind Medical$97K
  • Sumitomo Pharma America, Inc.$75K
  • Urovant Sciences Inc$48K
  • AbbVie$27K
  • Laborie Medical Technologies Corp.$24K
  • plus $25K from 36 others
$4,255in research payments, 2019–2025

Across 4 payments — averaging $1063.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$4K

What the payments were for

  • Consulting fees$51,57514%
  • Speaking & faculty fees$252,13569%
  • Travel & lodging$39,67111%
  • Food & beverage$23,5996%
  • Education$2620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$628,054 in reported general payments places this provider in the 95th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$518,153
Medicare patients
1,061
Services billed
6,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron402$436,263
MyrbetriqMirabegron100$106,791
Estradiol352$20,337
Oxybutynin Chloride ErOxybutynin Chloride117$2,849
NitrofurantoinNitrofurantoin Macrocrystal90$2,640
Methenamine Hippurate26$1,708
Tolterodine Tartrate ErTolterodine Tartrate14$1,455
Cephalexin73$1,079
Ciprofloxacin Hcl128$559
Tamsulosin Hcl33$501
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst29$422
CefuroximeCefuroxime Axetil25$409
Solifenacin Succinate29$408
Fluconazole65$406
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim128$380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$74,975$436,263402 claims
Astellas Pharma US IncMyrbetriq$648$106,791100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 274 urology providers in Maryland.

Other urology in Owings Mills

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →